title: Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production.
abstract: Excessive pro-inflammatory cytokine production in the bone marrow has been associated with the pathogenesis of myelodysplastic syndromes. We herein investigated the involvement of toll-like receptors and their endogenous ligands in the induction/maintenance of the inflammatory process in the marrow of patients with myelodysplastic syndromes. We evaluated the expression of toll-like receptors in marrow monocytes of patients (n=27) and healthy controls (n=25) by flow-cytometry and also assessed the activation of the respective signaling using a real-time polymerase chain reaction-based array. We measured the high mobility group box-1 protein, a toll-like receptor-4 ligand, in marrow plasma and long-term bone marrow culture supernatants by an enzyme-linked immunosorbent assay and we performed cross-over experiments using marrow plasma from patients and controls in the presence/absence of a toll-like receptor-4 inhibitor to evaluate the pro-inflammatory cytokine production by chemiluminescence. We assessed the apoptotic cell clearance capacity of patients' macrophages using a fluorescence microscopy-based assay. We found over-expression of toll-like receptor-4 in patients' marrow monocytes compared to that in controls; this over-expression was associated with up-modulation of 53 genes related to the respective signaling. Incubation of patients' monocytes with autologous, but not with normal, marrow plasma resulted in over-production of pro-inflammatory cytokines, an effect that was abrogated by the toll-like receptor-4 inhibitor suggesting that the pro-inflammatory cytokine production in myelodysplastic syndromes is largely mediated through toll-like receptor-4. The levels of high mobility group box-1 protein were increased in patients' marrow plasma and culture supernatants compared to the levels in controls. Patients' macrophages displayed an impaired capacity to engulf apoptotic cells and this defect was associated with excessive release of high mobility group box-1 protein by dying cells. A primary apoptotic cell clearance defect of marrow macrophages in myelodysplastic syndromes may contribute to the induction/maintenance of the inflammatory process through aberrant release of molecules inducing toll-like receptor-4 such as high mobility group box-1 protein.
authors: Department of Hematology, University of Crete School of Medicine, Heraklion, Greece.
authors: Maria
authors: M
authors: Velegraki
authors: Evaggelia
authors: E
authors: Papakonstanti
authors: Irene
authors: I
authors: Mavroudi
authors: Maria
authors: M
authors: Psyllaki
authors: Christos
authors: C
authors: Tsatsanis
authors: Anastasis
authors: A
authors: Oulas
authors: Ioannis
authors: I
authors: Iliopoulos
authors: Pavlos
authors: P
authors: Katonis
authors: Helen A
authors: HA
authors: Papadaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000276:immunology*; D001854:Bone Marrow Cells / Q000378:metabolism* / Q000473:pathology*; D002478:Cells, Cultured; D018920:Coculture Techniques; D018592:Cross-Over Studies; D005260:Female; D024243:HMGB1 Protein / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D051197:Toll-Like Receptor 4 / Q000096:biosynthesis / Q000502:physiology*
chemical_list: D024243:HMGB1 Protein; C585491:HMGB1 protein, human; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4
references: Blood. 2001 Nov 15;98(10):3058-65
references: 11698291
references: PLoS One. 2008 Aug 13;3(8):e2965
references: 18698424
references: Br J Haematol. 1998 Oct;103(1):176-88
references: 9792306
references: J Leukoc Biol. 2004 Sep;76(3):514-9
references: 15178705
references: J Clin Immunol. 2012 Apr;32(2):312-22
references: 22127462
references: J Leukoc Biol. 2009 Sep;86(3):573-6
references: 19414536
references: Leuk Res. 2002 Jul;26(7):677-86
references: 12008086
references: J Inflamm (Lond). 2010 Jun 17;7:30
references: 20565784
references: Nature. 2002 Jul 11;418(6894):191-5
references: 12110890
references: Leuk Lymphoma. 2000 Apr;37(3-4):405-14
references: 10752992
references: Rheumatology (Oxford). 2005 Sep;44(9):1101-7
references: 15928001
references: Nat Med. 2010 Jan;16(1):49-58
references: 19898489
references: Mol Med Rep. 2011 Jul-Aug;4(4):591-6
references: 21584497
references: Nat Med. 2010 Jan;16(1):59-66
references: 19966810
references: J Exp Med. 2008 Dec 22;205(13):3007-18
references: 19064698
references: Int J Med Sci. 2008 Jan 04;5(1):1-8
references: 18219369
references: Cytokine. 2010 Jan;49(1):1-9
references: 19775907
references: Blood. 2003 Apr 1;101(7):2591-600
references: 12517813
references: Int J Hematol. 2002 Apr;75(3):289-97
references: 11999358
references: Semin Oncol. 2011 Oct;38(5):627-34
references: 21943669
references: Br J Haematol. 2004 Jun;125(5):576-83
references: 15147372
references: Immunol Lett. 2001 Sep 3;78(2):97-101
references: 11672593
references: Nat Immunol. 2001 Aug;2(8):675-80
references: 11477402
references: Immunol Rev. 2005 Apr;204:27-42
references: 15790348
references: J Biol Chem. 2004 Feb 27;279(9):7370-7
references: 14660645
references: J Cell Biol. 2010 Jun 28;189(7):1059-70
references: 20584912
references: Blood. 2006 Feb 1;107(3):1156-65
references: 16223780
references: Clin Cancer Res. 2007 Feb 15;13(4):1154-60
references: 17317824
references: Nat Rev Immunol. 2005 Apr;5(4):331-42
references: 15803152
references: Int J Hematol. 2012 Jan;95(1):17-25
references: 22218882
references: Br J Haematol. 2007 Nov;139(4):578-89
references: 17916100
references: Nature. 2000 Aug 17;406(6797):782-7
references: 10963608
references: Nat Rev Immunol. 2004 Jul;4(7):499-511
references: 15229469
references: Eur J Immunol. 2004 Jun;34(6):1503-12
references: 15162419
references: Blood. 2006 Dec 15;108(13):4170-7
references: 16940419
references: Annu Rev Immunol. 2010;28:367-88
references: 20192808
references: Hematol Rep. 2010 Jan 26;2(1):e4
references: 22184517
references: Exp Mol Pathol. 2010 Apr;88(2):293-8
references: 20132814
references: Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11942-7
references: 20547845
references: Br J Haematol. 2002 Mar;116(4):817-25
references: 11886386